Thrombolytic therapy in the treatment of acute ischemic stroke

Journal of Pharmacy Technology

Volumn 14, Issue 3, 1998, Pages 101-105

  Matuszewski, Karl A ^a,b   Seeger, John D ^c  

^a University HealthSystem Consortium   (United States)

^b RUSH UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Stroke; Thrombolysis; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; STREPTOKINASE; TICLOPIDINE; WARFARIN;

ACUTE DISEASE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0031835666     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Matchar DB, Duncan PW. Cost of stroke. Stroke 1994;3:9-12.
2. Adams RD, Victor M. Cerebrovascular diseases. In: Day W, Navroza M, eds. Principles of neurology. 4th ed. New York: McGraw-Hill, 1989:617-24.
3. Becker RC, Ansell J. Antithrombotic therapy: an abbreviated reference for clinicians. Arch Intern Med 1995;155:149-61.
4. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
5. Genentech Activase stroke use within three hours to get aid from NINDS educational effort; company conducting postmarketing efficacy/safety study. FDC Rep 1996;June 24:5-6.
6. 1997 Drug topics red book. Montvale, NJ: Medical Economics, 1997:130.
7. Multicentre Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
8. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in the treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
9. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-6.
10. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
11. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
12. Spector W. Functional disability scales. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 115-29.
13. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167-74.
14. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke. Neurology 1996;47:835-9.
15. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolysis therapy for acute ischaemic stroke. Lancet 1997;350:607-14.
16. Fisher M, Pessin MS, Furian AJ. ECASS: lessons for future thrombolytic stroke trials. JAMA 1995;274:1058-9.